Abdelghani Achab

Statistics

Publications

Citations

317

H-Index

Active since

2011

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Quantitative BioSciences

Discovery Laboratories (United States)

WuXi AppTec (China)

Abdelghani Achab is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

2011–2022

Publications

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

Brandon Vara, Samuel M. Levi, Abdelghani Achab et al. · ACS Medicinal Chemistry Letters · 2021 · 50 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Structural characterization of nonactive site, TrkA-selective kinase inhibitors

Hua-Poo Su, Keith Rickert, Christine Burlein et al. · Proceedings of the National Academy of Sciences · 2016 · 48 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy

Hongjun Zhang, K. Liu, Qinglin Pu et al. · ACS Medicinal Chemistry Letters · 2019 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors

Xiaohua Huang, Gerald W. Shipps, Cliff C. Cheng et al. · ACS Medicinal Chemistry Letters · 2011 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy

Matthew J. Mitcheltree, Derun Li, Abdelghani Achab et al. · ACS Medicinal Chemistry Letters · 2020 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

1–5 of 11